Glucose-lowering therapies, particularly sodium-glucose cotransporter-2 (SGLT-2) inhibitors and metformin, demonstrated potential neuroprotective effects, reducing the risk of dementia and cognitive impairment. This evidence concerns the gene SLC5A2 and Cognitive impairment.